Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000197112 | SCV000249985 | uncertain significance | not provided | 2015-05-12 | criteria provided, single submitter | clinical testing | TAAD is a genetically heterogeneous disorder characterized by aortic dilatation, aneurysms, dissections and/or aneurysms of other major arteries. p.Pro1195Ala (P1195A) CCA>GCA: c.3583 C>G in exon 50 of the COL5A2 gene (NM_000393.3)A variant of unknown significance has been identified in the COL5A2 gene. The P1195A variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The P1195A variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The P1195A variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. However, in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Additionally, no missense mutations in nearby residues have been reported in association with EDS suggesting this region of the protein may be tolerant of change. Finally, the P1195A variant does not affect a Glycine residue in a Gly-X-Y motif in the triple helical region of the COL5A2 gene, where the majority of missense mutations. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. This result cannot be interpreted for diagnosis or used for family member screening at this time. This variant was found in TAADV2-PANCARD. |
Invitae | RCV003765244 | SCV004642143 | likely benign | Ehlers-Danlos syndrome, classic type, 1 | 2022-12-07 | criteria provided, single submitter | clinical testing |